ProfileGDS5678 / 1434851_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 40% 39% 39% 39% 55% 38% 38% 39% 39% 39% 39% 39% 40% 39% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9533240
GSM967853U87-EV human glioblastoma xenograft - Control 22.9029739
GSM967854U87-EV human glioblastoma xenograft - Control 32.8934139
GSM967855U87-EV human glioblastoma xenograft - Control 42.8365439
GSM967856U87-EV human glioblastoma xenograft - Control 53.3372255
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9431838
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9358438
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.875439
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8792739
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.876339
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8916539
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8575539
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.925940
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8921239